Edding Genor Group Holdings Limited (FRA:67N0)

Market Cap	573.47M
Revenue (ttm)	26.63M
Net Income (ttm)	3.44M
Shares Out	n/a
EPS (ttm)	0.01
PE Ratio	166.85
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	263
Open	0.2740
Previous Close	0.2880
Day's Range	0.2740 - 0.2740
52-Week Range	0.1850 - 0.5700
Beta	n/a
RSI	31.22
Earnings Date	Mar 27, 2026

About FRA:67N0

Edding Genor Group Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat soli...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 67N0

Financial Performance

Financial numbers in CNY